{"pmid":32458370,"title":"Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide.","text":["Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide.","Many healthcare resources have been and continue to be allocated to the management of patients with COVID-19. Therefore, the ongoing care of patients receiving oral anticoagulation with warfarin is likely to be compromised amid this unprecedented crisis. This article discusses a stepwise algorithm for the management of outpatient warfarin therapy. Alternative management strategies are presented and discussed, including alternative pharmacological therapy options and self-monitoring. Our algorithm aims to help clinicians safely optimize the treatment of patients requiring anticoagulation therapy in the context of the global response to the current pandemic.","Am J Cardiovasc Drugs","Kow, Chia Siang","Sunter, Wendy","Bain, Amie","Zaidi, Syed Tabish Razi","Hasan, Syed Shahzad","32458370"],"abstract":["Many healthcare resources have been and continue to be allocated to the management of patients with COVID-19. Therefore, the ongoing care of patients receiving oral anticoagulation with warfarin is likely to be compromised amid this unprecedented crisis. This article discusses a stepwise algorithm for the management of outpatient warfarin therapy. Alternative management strategies are presented and discussed, including alternative pharmacological therapy options and self-monitoring. Our algorithm aims to help clinicians safely optimize the treatment of patients requiring anticoagulation therapy in the context of the global response to the current pandemic."],"journal":"Am J Cardiovasc Drugs","authors":["Kow, Chia Siang","Sunter, Wendy","Bain, Amie","Zaidi, Syed Tabish Razi","Hasan, Syed Shahzad"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458370","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s40256-020-00415-z","e_drugs":["Warfarin"],"topics":["Prevention"],"weight":1,"_version_":1667967698976374784,"score":9.490897,"similar":[{"pmid":32440883,"title":"Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum.","text":["Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum.","Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar to sepsis-associated disseminated intravascular coagulopathy (DIC), COVID-19- induced coagulopathy (CIC) appears to be more prothrombotic than hemorrhagic. It has been postulated that CIC may be an uncontrolled immunothrombotic response to COVID-19, and there is growing evidence of venous and arterial thromboembolic events in these critically ill patients. Clinicians around the globe are challenged with rapidly identifying reasonable diagnostic, monitoring and anticoagulant strategies to safely and effectively manage these patients. Thoughtful use of proven, evidence-based approaches must be carefully balanced with integration of rapidly emerging evidence and growing experience. The goal of this document is to provide guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of anticoagulant therapies in patients with COVID-19. We discuss in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19.","J Thromb Thrombolysis","Barnes, Geoffrey D","Burnett, Allison","Allen, Arthur","Blumenstein, Marilyn","Clark, Nathan P","Cuker, Adam","Dager, William E","Deitelzweig, Steven B","Ellsworth, Stacy","Garcia, David","Kaatz, Scott","Minichiello, Tracy","32440883"],"abstract":["Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar to sepsis-associated disseminated intravascular coagulopathy (DIC), COVID-19- induced coagulopathy (CIC) appears to be more prothrombotic than hemorrhagic. It has been postulated that CIC may be an uncontrolled immunothrombotic response to COVID-19, and there is growing evidence of venous and arterial thromboembolic events in these critically ill patients. Clinicians around the globe are challenged with rapidly identifying reasonable diagnostic, monitoring and anticoagulant strategies to safely and effectively manage these patients. Thoughtful use of proven, evidence-based approaches must be carefully balanced with integration of rapidly emerging evidence and growing experience. The goal of this document is to provide guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of anticoagulant therapies in patients with COVID-19. We discuss in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19."],"journal":"J Thromb Thrombolysis","authors":["Barnes, Geoffrey D","Burnett, Allison","Allen, Arthur","Blumenstein, Marilyn","Clark, Nathan P","Cuker, Adam","Dager, William E","Deitelzweig, Steven B","Ellsworth, Stacy","Garcia, David","Kaatz, Scott","Minichiello, Tracy"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440883","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11239-020-02138-z","keywords":["anticoagulation","covid-19","direct oral anticoagulant","prophylaxis","stewardship","venous thromboembolism"],"locations":["North American"],"topics":["Treatment"],"weight":1,"_version_":1667535119517220866,"score":147.57129},{"pmid":32327293,"pmcid":"PMC7158763","title":"Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.","text":["Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.","The current outbreak of COVID-19 (coronavirus) has been identified by World Health Organization (WHO) as a global pandemic. With the emergence of the COVID-19 virus and considering the lack of effective pharmaceutical treatment for it, there is an urgent need to identify safe and effective drugs or potential adjuvant therapy in this regard. Bioactive lipids with an array of known health-promoting properties can be suggested as effective agents in alleviating acute respiratory stress induced by virus. The bioactive lipid amide, oleoylethanolamide (OEA), due to several distinctive homeostatic properties, including anti-inflammatory activities, modulation of immune response, and anti-oxidant effects can be considered as a novel potential pharmacological alternative for the management of COVID-19.","Arch Med Res","Ghaffari, Samad","Roshanravan, Neda","Tutunchi, Helda","Ostadrahimi, Alireza","Pouraghaei, Mahboub","Kafil, Behnam","32327293"],"abstract":["The current outbreak of COVID-19 (coronavirus) has been identified by World Health Organization (WHO) as a global pandemic. With the emergence of the COVID-19 virus and considering the lack of effective pharmaceutical treatment for it, there is an urgent need to identify safe and effective drugs or potential adjuvant therapy in this regard. Bioactive lipids with an array of known health-promoting properties can be suggested as effective agents in alleviating acute respiratory stress induced by virus. The bioactive lipid amide, oleoylethanolamide (OEA), due to several distinctive homeostatic properties, including anti-inflammatory activities, modulation of immune response, and anti-oxidant effects can be considered as a novel potential pharmacological alternative for the management of COVID-19."],"journal":"Arch Med Res","authors":["Ghaffari, Samad","Roshanravan, Neda","Tutunchi, Helda","Ostadrahimi, Alireza","Pouraghaei, Mahboub","Kafil, Behnam"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327293","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.arcmed.2020.04.006","keywords":["bioactive lipids","covid-19","coronavirus","oea","oleoylethanolamide"],"e_drugs":["oleoylethanolamide","Amides","Lipids"],"topics":["Treatment"],"weight":1,"_version_":1666138494588682240,"score":136.65228},{"pmid":32311652,"pmcid":"PMC7194953","title":"Diabetes self-management amid COVID-19 pandemic.","text":["Diabetes self-management amid COVID-19 pandemic.","BACKGROUND AND AIMS: COVID-19 pandemic has challenged the physician-centered approach of diabetes care in India that is primarily based on routine clinic visits. We aim to review the various aspects of patient-centered care via diabetes self-management education based on available literature. METHODS: This is a narrative review using Pubmed, EMBASE and Google Scholar search till March 29, 2020. Search terms were \"COVID-19\", \"diabetes self-care\", \"diabetes self-management education\", \"DSME\", \"diabetes self-management in India\", \"diabetes self-care in India\" and \"DSME in India\". RESULTS: We have discussed an educational plan on diabetes self-management that can be adopted for people with diabetes mellitus in our country amid the ongoing pandemic. We have also identified the barriers to diabetes self-management in the current scenario and suggested possible solutions to overcome those. CONCLUSIONS: We have reemphasized the need for a simultaneous patient-centered approach in routine diabetes care that has to be coordinated by a multidisciplinary team amid the ongoing COVID-19 pandemic.","Diabetes Metab Syndr","Banerjee, Mainak","Chakraborty, Soumen","Pal, Rimesh","32311652"],"abstract":["BACKGROUND AND AIMS: COVID-19 pandemic has challenged the physician-centered approach of diabetes care in India that is primarily based on routine clinic visits. We aim to review the various aspects of patient-centered care via diabetes self-management education based on available literature. METHODS: This is a narrative review using Pubmed, EMBASE and Google Scholar search till March 29, 2020. Search terms were \"COVID-19\", \"diabetes self-care\", \"diabetes self-management education\", \"DSME\", \"diabetes self-management in India\", \"diabetes self-care in India\" and \"DSME in India\". RESULTS: We have discussed an educational plan on diabetes self-management that can be adopted for people with diabetes mellitus in our country amid the ongoing pandemic. We have also identified the barriers to diabetes self-management in the current scenario and suggested possible solutions to overcome those. CONCLUSIONS: We have reemphasized the need for a simultaneous patient-centered approach in routine diabetes care that has to be coordinated by a multidisciplinary team amid the ongoing COVID-19 pandemic."],"journal":"Diabetes Metab Syndr","authors":["Banerjee, Mainak","Chakraborty, Soumen","Pal, Rimesh"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311652","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.dsx.2020.04.013","keywords":["covid-19","dsme","diabetes mellitus","diabetes self-care","diabetes self-management education"],"locations":["India","India","India","India"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Prevention"],"weight":1,"_version_":1666138491275182080,"score":135.89001},{"pmid":32426292,"pmcid":"PMC7212352","title":"Oral Chemotherapy for Treatment of Lung Cancer.","text":["Oral Chemotherapy for Treatment of Lung Cancer.","The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer.","Front Oncol","Jonna, Sushma","Reuss, Joshua E","Kim, Chul","Liu, Stephen V","32426292"],"abstract":["The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer."],"journal":"Front Oncol","authors":["Jonna, Sushma","Reuss, Joshua E","Kim, Chul","Liu, Stephen V"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426292","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3389/fonc.2020.00793","keywords":["capecitabine","chemotherapy","etoposide","oral therapy","temozolomide","topotecan","vinorelbine"],"topics":["Prevention"],"weight":1,"_version_":1667252837948588033,"score":134.0782},{"pmid":32298480,"title":"Management of Infantile Hemangiomas during the COVID Pandemic.","text":["Management of Infantile Hemangiomas during the COVID Pandemic.","The COVID-19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long-term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of infantile hemangiomas via telemedicine. FDA/EMA approved monitoring guidelines, clinical practice guidelines and relevant, up-to-date publications regarding initiation and monitoring of beta-blocker therapy were used to inform the recommendations. Clinical decision-making guidelines about when telehealth is an appropriate alternative to in-office visits, including medication initiation, dosage changes, and ongoing evaluation are included. The importance of communication with caregivers in the context of telemedicine is discussed and online resources for both hemangioma education and for propranolol therapy provided.","Pediatr Dermatol","Frieden, Ilona J","Puttgen, Katherine B","Drolet, Beth A","Garzon, Maria C","Chamlin, Sarah L","Pope, Elena","Mancini, Anthony J","Lauren, Christine T","Mathes, Erin F","Siegel, Dawn H","Gupta, Deepti","Haggstrom, Anita N","Tollefson, Megha M","Baselga, Eulalia","Morel, Kimberly D","Shah, Sonal D","Holland, Kristen E","Adams, Denise M","Horii, Kimberly A","Newell, Brandon D","Powell, Julie","McCuaig, Catherine C","Nopper, Amy J","Metry, Denise W","Maguiness, Sheilagh","32298480"],"abstract":["The COVID-19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long-term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of infantile hemangiomas via telemedicine. FDA/EMA approved monitoring guidelines, clinical practice guidelines and relevant, up-to-date publications regarding initiation and monitoring of beta-blocker therapy were used to inform the recommendations. Clinical decision-making guidelines about when telehealth is an appropriate alternative to in-office visits, including medication initiation, dosage changes, and ongoing evaluation are included. The importance of communication with caregivers in the context of telemedicine is discussed and online resources for both hemangioma education and for propranolol therapy provided."],"journal":"Pediatr Dermatol","authors":["Frieden, Ilona J","Puttgen, Katherine B","Drolet, Beth A","Garzon, Maria C","Chamlin, Sarah L","Pope, Elena","Mancini, Anthony J","Lauren, Christine T","Mathes, Erin F","Siegel, Dawn H","Gupta, Deepti","Haggstrom, Anita N","Tollefson, Megha M","Baselga, Eulalia","Morel, Kimberly D","Shah, Sonal D","Holland, Kristen E","Adams, Denise M","Horii, Kimberly A","Newell, Brandon D","Powell, Julie","McCuaig, Catherine C","Nopper, Amy J","Metry, Denise W","Maguiness, Sheilagh"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298480","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/pde.14196","e_drugs":["Propranolol"],"topics":["Prevention"],"weight":1,"_version_":1666138493336682496,"score":127.414795}]}